LEAP THERAPEUTICS, INC. (LPTX)
2025-06-30 | ||||
|---|---|---|---|---|
| Restructuring charges | 4,527 | |||
| Research and development | 10,537 | |||
| General and administrative | 1,817 | |||
| Total operating expenses | 16,881 | |||
| Loss from operations | -16,881 | |||
| Interest income | 246 | |||
| Interest expense | 7 | |||
| Foreign currency gain (loss) | -2 | |||
| Australian research and development incentives | 1 | |||
| Net loss | -16,643 | |||
| Net loss attributable to common stockholders | -16,643 | |||
| Earnings per share, basic | -0.4 | |||
| Earnings per share, diluted | -0.4 | |||
| Weighted average number of shares outstanding, basic | 41,444,979 | |||
| Weighted average number of shares outstanding, diluted | 41,444,979 | |||